Treatment of Classical Hodgkin Lymphoma in Adults Over 60 — Early Favorable Stage (I–II)
Classical Hodgkin lymphoma diagnosed at an early, favorable stage in patients over 60 years of age calls for a treatment approach carefully shaped around tolerability. This protocol addresses that specific clinical picture.
Clinical scenario
This protocol applies to adults over 60 years of age with confirmed classical Hodgkin lymphoma at early stage (I or II), classified as favorable — no high-risk factors present. Age is the defining patient characteristic that drives the particular treatment selection used here.
Treatment approach
For this age group, the chemotherapy regimen is modified compared to standard treatment in younger patients; the modification is made specifically to reduce the risk of pulmonary toxicity. For patients over 60 who are not candidates for chemotherapy, a separate treatment path applies. The complete regimen, eligibility criteria, and full sequencing are available in the structured protocol.
Treatment goals
Response is assessed by PET-CT imaging. The clinical target is a negative scan result — a Deauville score of 1, 2, or 3, indicating no areas of concern — together with complete disease remission.
References
Older patients (over 60 years of age) with early favorable HL may benefit from omitting the bleomycin in ABVD to avoid pulmonary (lung) toxicity.
Older patients who are not candidates for chemotherapy may have radiation therapy alone.
A score of 1, 2 or 3 is considered negative, meaning there are no areas of concern.
View source ↗